NCT05099445View on ClinicalTrials.gov

Study to Evaluate the Pharmacokinetics, Safety, and Pharmacodynamics of INCB000928 in Participants With Impaired Renal Function and Hemodialysis

PHASE1CompletedINTERVENTIONAL
Enrollment

48

Participants

Timeline

Start Date

December 14, 2021

Primary Completion Date

February 19, 2023

Study Completion Date

February 27, 2023

Conditions
Renal ImpairmentHemodialysis
Interventions
DRUG

INCB000928

INCB000928 200 mg will be administered on Day 1 of each treatment period.

Trial Locations (5)

32809

Orlando Clinical Research Center, Orlando

33014

Clinical Pharmacology of Miami, Hialeah

33147

Advanced Pharma, Miami

55114

Nucleus Network Minneapolis Clinic, Saint Paul

92377

Inland Empire Liver Foundation, Rialto

Sponsors

Lead Sponsor

Incyte Corporation
All Listed Sponsors
lead

Incyte Corporation

INDUSTRY